CORRIGENDUM

DOI: 10.3892/ijmm.2021.4891

TUSC8 inhibits the development of osteosarcoma by sponging miR-197-3p and targeting EHD2

 $\operatorname{\mathsf{HONGWU}}$ FAN, TONG LIU, HAO TIAN and SHANYONG ZHANG

Int J Mol Med 46: 1311-1320, 2020; DOI: 10.3892/ijmm.2020.4684

Subsequently to the publication of this article, the authors have realized that Fig. 2D contained a duplication error, which arose during the assembly of the figures; specifically, the upper-left panel in Fig. 2D, showing the results of the MG-63/pcDNA3.1 Transwell assay experiment, were inadvertently repeated in Fig. 5E. The corrected version of Fig. 2, showing the correct data for Fig. 2D, is shown on the next page.

The authors wish to emphasize that this correction does not change either the interpretation or the original conclusions of their study. The authors are grateful to the Editor of *International Journal of Molecular Medicine* for granting them the opportunity to publish this corrigendum, and all the authors agree with the correction. Furthermore, the authors apologize to the Editor of *International Journal of Molecular Medicine* and to readership for any inconvenience caused.



This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) License.




Figure 5. TUSC8 inhibits OS development by regulating EHD2. (A) The mRNA and protein levels of EHD2 were evaluated in sh-EHD2-transfected cells. (B and C) CCK-8 and colony formation assays were used to assess cell proliferation in transfected cells. (D) Flow cytometry was used to measure cell apoptosis. (E and F) Transwell assays were carried out to evaluate cell migration and invasion. (G) Western blot analysis was used to evaluate epithelial-mesenchymal transition. *P<0.05 and *P<0.05.